The likelihood for reoccurrence of active disease was not significantly associated with the time in inactive disease before ETA discontinuation (Fig. 1) and other clinical parameters such as JIA category, gender, ANA, and HLA-B27 positivity, response to therapy to ETA within the first 6 months, duration between JIA onset and start of DMARD treatment and the cumulative time under MTX or ETA before ETA discontinuation after achieving inactive disease. Here, BTG3 is linked to juvenile idiopathic arthritis.